Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's sales have experienced significant growth, with reported figures of $803 million in 2024, and management forecasts an increase to between $940 million and $955 million for the upcoming year. The company's strategic focus on cardiopulmonary solutions and neuromodulation devices positions it well within high-demand segments, indicating robust revenue potential. Additionally, projections for the aura6000 device suggest a potential increase in market share and sales, with estimates ranging from $120 million in 2027 to $280 million by 2029 under favorable conditions, contributing positively to LivaNova's growth outlook.

Bears say

LivaNova's financial outlook is negatively impacted by anticipated revenue growth slowing to the low-single digits, primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. The company's operating margins are expected to contract, contributing to earnings falling below market consensus. Additional risks include the potential failure to secure FDA approval for the aura6000, coupled with slower than expected growth and weaker margin improvements in both its Neuromodulation and Cardiopulmonary divisions.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.